HDAC7 (Ab-155) Antibody

What is the functional significance of HDAC7 and its phosphorylation at serine 155?

HDAC7 functions primarily as an epigenetic regulator responsible for the deacetylation of lysine residues on the N-terminal regions of core histones (H2A, H2B, H3, and H4). This deacetylation process provides a tag for epigenetic repression and plays crucial roles in transcriptional regulation, cell cycle progression, and developmental events . Phosphorylation at serine 155 represents a critical regulatory mechanism that modulates HDAC7's activity and subcellular localization. The phosphorylation status of this residue influences HDAC7's ability to form multiprotein complexes necessary for its repressive functions, thereby affecting its biological activity in different cellular contexts . During processes such as muscle differentiation, phosphorylation-dependent shuttling of HDAC7 from the nucleus to the cytoplasm allows the expression of myocyte enhancer factors (MEF2A, MEF2B, and MEF2C), highlighting how this post-translational modification serves as a molecular switch governing HDAC7's repressive capabilities .

How does HDAC7 (Ab-155) antibody differ from other HDAC7 antibodies in experimental applications?

The HDAC7 (Ab-155) antibody is a rabbit polyclonal antibody specifically designed to recognize the phosphorylated form of HDAC7 at serine 155, using a synthetic non-phosphopeptide derived from human HDAC7A around the phosphorylation site (T-V-S(p)-E-P) . This phospho-specific recognition distinguishes it from general HDAC7 antibodies such as the HDAC7 (A-7) mouse monoclonal antibody, which detects the total HDAC7 protein regardless of phosphorylation status .

When designing experiments, researchers should consider that HDAC7 (Ab-155) enables specific investigation of the phosphorylated state, which is particularly valuable when studying signaling pathways and cellular responses where HDAC7 activation state changes. In contrast, the A-7 antibody offers broader detection of HDAC7 across multiple applications including western blotting, immunoprecipitation, immunofluorescence, and ELISA . For comprehensive studies of HDAC7 regulation, researchers often employ both phospho-specific and total HDAC7 antibodies to distinguish between changes in phosphorylation state versus total protein expression levels.

What experimental validation methods confirm HDAC7 (Ab-155) antibody specificity?

Validating antibody specificity is critical for reliable experimental results. For HDAC7 (Ab-155) antibody, several approaches have been documented:

• Western blot validation: Demonstrated through analysis of JK cells, showing specific recognition of phosphorylated HDAC7 at the expected molecular weight . Researchers should observe a distinct band corresponding to phosphorylated HDAC7 that can be eliminated by phosphatase treatment.

• Peptide competition assays: Comparing antibody binding with and without pre-incubation with phosphorylated versus non-phosphorylated peptides corresponding to the S155 region helps confirm specificity.

• Phosphorylation-state manipulation: Treating cells with phosphatase inhibitors versus phosphatases to demonstrate differential detection demonstrates the antibody's phospho-specificity.

• Knockout/knockdown controls: Using HDAC7 knockout models or siRNA-mediated knockdown provides crucial negative controls. The HDAC7-specific siRNA corresponding to bases 579-597 of murine HDAC7 mRNA has been effectively used for this purpose .

These validation approaches should be incorporated into experimental design to ensure confident interpretation of results when using this antibody for phosphorylation-specific applications.

What are the optimal protocols for using HDAC7 (Ab-155) antibody in Western blotting?

For optimal Western blotting results with HDAC7 (Ab-155) antibody, researchers should follow these methodological guidelines:

A standardized protocol employing these considerations will maximize detection sensitivity while maintaining specificity for the phosphorylated S155 epitope of HDAC7.

How can researchers effectively establish and validate HDAC7 knockdown models?

Establishing reliable HDAC7 knockdown models is essential for studying its functional significance. Based on published methodologies, researchers should consider:

• siRNA approach: Implement the validated siRNA-mediated knockdown system targeting bases 579-597 of murine HDAC7 mRNA (sequence: AGACAAGAGCAAGCGAAGU) . This approach has been successfully used in T-cell models with verification via both mRNA and protein expression.

• Transfection optimization: For T-cell lines like DPK cells, Amaxa Nucleofector solution V with program B13 has proven effective, with cell sorting 3 hours post-transfection to select cells with high transfection efficiency .

• Knockdown verification: Validate HDAC7 reduction at both:

  • Protein level: Western blotting using HDAC7-specific antibodies

  • mRNA level: RT-qPCR with primers specific to HDAC7 transcript

• Functional validation: Assess known HDAC7-regulated genes (e.g., MEF2-regulated genes) to confirm functional consequences of knockdown.

• Control selection: Use control siRNAs with 2-base mismatches (e.g., AGACAAGAUUAAGCGAAGU) to rule out off-target effects .

When analyzing knockdown phenotypes, researchers should account for the half-life of existing HDAC7 protein and consider inducible systems for studying long-term effects of HDAC7 depletion.

What experimental approaches help distinguish HDAC7 functions from other class IIa HDACs?

Distinguishing HDAC7-specific functions from those of related class IIa HDACs (HDAC4, HDAC5, HDAC9) requires careful experimental design:

• Domain-specific mutants: Generate phosphorylation-resistant mutants (e.g., S155A) to specifically study the role of phosphorylation at this site without affecting other HDACs .

• Rescue experiments: After HDAC7 knockdown, perform rescue experiments with wild-type or mutant HDAC7 resistant to siRNA (through silent mutations) to confirm phenotype specificity.

• ChIP-seq analysis: Perform chromatin immunoprecipitation sequencing to identify HDAC7-specific genomic binding sites, using HDAC7 (Ab-155) antibody to specifically track phosphorylated HDAC7 occupancy .

• MEF2 reporter assays: Since class IIa HDACs differentially regulate MEF2 transcription factors, MEF2 reporter assays with specific HDAC7 manipulations can distinguish its effects from other family members .

• Tissue-specific analyses: Leverage the tissue-specific expression patterns of HDAC7 (particularly in thymic and vascular tissues) to design experiments highlighting its unique functions .

These approaches collectively help delineate HDAC7-specific functions while controlling for potential compensatory effects from other class IIa HDACs.

How is HDAC7 involved in cancer biology and what experimental models best capture these mechanisms?

HDAC7 has emerged as a significant player in oncogenesis through several key mechanisms:

• RAS-transformation dependency: HDAC7 levels increase in RAS-transformed cells, where it supports proliferation and cancer stem-like cell maintenance. Researchers studying this connection should employ isogenic cell line pairs with and without RAS mutations to isolate HDAC7-specific effects .

• Cancer stem cell regulation: HDAC7 is highly expressed in cancer stem cells of breast and ovarian origins, contributing to stemness maintenance . Experimental models utilizing:

  • Mammosphere/tumorsphere formation assays

  • CD44+/CD24- cell sorting in breast cancer models

  • Serial transplantation studies in immunocompromised mice
    allow for comprehensive assessment of HDAC7's role in stemness.

• Epigenetic landscape modification: HDAC7-mediated changes in histone acetylation affect chromatin architecture and accessibility. Researchers should incorporate:

  • ATAC-seq to assess chromatin accessibility changes

  • ChIP-seq for histone modification mapping

  • Single-cell sequencing to capture cellular heterogeneity

• Neoplastic transformation cooperation: HDAC7 upregulation cooperates with other oncogenic events in both rodent and human cellular transformation models . Researchers can assess this using:

  • Soft agar colony formation assays

  • Focus formation tests

  • In vivo tumorigenicity assays with HDAC7 overexpression/knockdown

MCF10A human mammary epithelial cells provide an excellent model system for studying HDAC7's role in oncogenesis, offering opportunities to examine effects on proliferation, stemness, and transformation in a well-characterized cellular background .

What role does HDAC7 play in T-cell development and autoimmunity regulation?

HDAC7 functions as a crucial regulator in T-cell development and autoimmune processes through several mechanisms:

• Thymic selection regulation: HDAC7 controls an extensive set of genes differentially expressed during both positive and negative thymic selection . Experimental approaches to study this include:

  • Thymocyte-specific HDAC7 conditional knockout models

  • HDAC7 mutant overexpression systems in thymic organ cultures

  • Transcriptomic profiling comparing wild-type vs HDAC7-deficient developing thymocytes

• Natural Killer T (NKT) cell programming: HDAC7 controls thymic effector programming of NKT cells, with implications for tissue-specific autoimmunity . Research methodologies should include:

  • Flow cytometric analysis of NKT cell development markers

  • Functional assays measuring cytokine production by NKT cells

  • In vivo models of autoimmunity with NKT cell adoptive transfer

• Transcriptional repression complexes: HDAC7 forms complexes with co-repressors like mSin3A to regulate gene expression in T cells . Investigations should employ:

  • Co-immunoprecipitation assays to identify HDAC7 binding partners

  • ChIP-seq to map genomic regions co-occupied by HDAC7 and its partners

  • Reporter gene assays to quantify repression strength

• Phosphorylation-dependent signaling: TCR activation triggers HDAC7 phosphorylation, altering its subcellular localization and function . Researchers should analyze:

  • Kinetics of HDAC7 phosphorylation using phospho-specific antibodies

  • Nuclear/cytoplasmic fractionation to track HDAC7 shuttling

  • Phosphorylation-resistant HDAC7 mutants to assess functional consequences

Understanding these HDAC7-mediated mechanisms provides insights into autoimmune pathogenesis and potential therapeutic interventions targeting epigenetic regulation in immune disorders.

What experimental approaches best characterize HDAC7's transcriptional regulatory networks?

Characterizing HDAC7's transcriptional regulatory networks requires integrative experimental strategies:

• Gene expression profiling: Compare transcriptomes in systems with perturbed HDAC7 function, such as:

  • Overexpression of HDAC7 mutants that convert it from a repressor to an activator

  • Expression of phosphorylation-resistant HDAC7 mutants that maintain repressive function during activation

  • HDAC7 knockdown/knockout systems

• Direct target identification: Distinguish direct from indirect HDAC7 targets using:

  • ChIP-seq to map HDAC7 binding sites genome-wide

  • CUT&RUN for higher resolution protein-DNA interaction mapping

  • Rapid induction systems (e.g., degron-tagged HDAC7) to identify primary response genes

• Interaction partner mapping: Identify HDAC7 co-repressors and interaction partners via:

  • Proximity labeling approaches (BioID, APEX)

  • Immunoprecipitation followed by mass spectrometry

  • Yeast two-hybrid screening focused on tissue-specific interactors

• Functional validation: Confirm regulatory relationships through:

  • Reporter gene assays with wild-type and mutated regulatory elements

  • CRISPR interference/activation at HDAC7 binding sites

  • Northern blot verification using radiolabeled probes (e.g., 32P-ATP labeled 40-mer oligonucleotides) and normalization to housekeeping genes like GAPDH

These approaches collectively build a comprehensive picture of HDAC7's position within transcriptional regulatory networks and identify context-specific functions across different cellular systems.

How can researchers address inconsistent detection of phosphorylated HDAC7?

Inconsistent detection of phosphorylated HDAC7 represents a common technical challenge. Researchers should implement these troubleshooting approaches:

• Sample preparation optimization:

  • Ensure rapid sample processing with consistent cold temperature maintenance

  • Use phosphatase inhibitor cocktails containing both serine/threonine and tyrosine phosphatase inhibitors

  • Avoid repeated freeze-thaw cycles of protein samples

• Antibody validation and handling:

  • Confirm antibody lot-to-lot consistency with positive control samples

  • Store antibody according to manufacturer recommendations (e.g., at -20°C in small aliquots to prevent freeze-thaw cycles)

  • Validate specificity using competing phosphopeptides

• Signal enhancement strategies:

  • Employ signal amplification systems for low abundance phosphoproteins

  • Increase protein loading while maintaining good resolution

  • Consider phosphoprotein enrichment techniques prior to Western blotting

• Technical validation:

  • Use multiple detection methods (e.g., Western blot and immunofluorescence)

  • Confirm phosphorylation with orthogonal approaches (e.g., mass spectrometry)

  • Include both positive controls (phosphatase inhibitor-treated samples) and negative controls (phosphatase-treated samples)

The table below summarizes troubleshooting approaches for common HDAC7 phospho-detection issues:

What approaches help resolve contradictory data in HDAC7 functional studies?

When faced with contradictory results in HDAC7 research, systematic approaches help resolve discrepancies:

• Cell type and context considerations:

  • HDAC7 functions differently across cell types - compare results in identical cellular backgrounds

  • Document activation state of cells, as HDAC7 activity is highly context-dependent

  • Consider the microenvironment influence, particularly in tumorigenic settings

• Isoform and modification specificity:

  • Verify which HDAC7 isoform was studied (HDAC7A vs other variants)

  • Assess phosphorylation status at multiple sites beyond S155

  • Determine if contradictory results stem from different post-translational modifications

• Experimental approach harmonization:

  • Standardize knockdown efficiency measurements across studies

  • Align timepoints for acute vs chronic HDAC7 perturbation

  • Compare genetic vs pharmacological inhibition approaches

• Compensatory mechanism assessment:

  • Evaluate upregulation of other class IIa HDACs following HDAC7 manipulation

  • Perform combinatorial knockdown of multiple HDACs to address redundancy

  • Examine temporal dynamics of compensatory responses

By systematically addressing these variables, researchers can reconcile apparently contradictory findings and develop a more nuanced understanding of context-dependent HDAC7 functions.

How can researchers effectively compare and integrate HDAC7 datasets from different experimental platforms?

Integrating HDAC7 data across different experimental platforms requires careful methodological considerations:

• Data normalization strategies:

  • For transcriptomic data, implement cross-platform normalization methods (e.g., quantile normalization)

  • When comparing ChIP-seq datasets, use consistent peak calling parameters and standardized signal quantification

  • Normalize protein expression data to consistent housekeeping controls across platforms

• Statistical approach alignment:

  • Apply consistent statistical thresholds for significance determination

  • Use meta-analysis techniques to combine p-values from independent studies

  • Implement Bayesian integration methods for heterogeneous data types

• Functional validation across platforms:

  • Confirm key findings using orthogonal techniques (e.g., validate RNA-seq with qPCR)

  • Prioritize gene targets identified across multiple platforms

  • Design validation experiments targeting conserved HDAC7 functions

• Bioinformatic integration frameworks:

  • Employ pathway and network analysis to identify functional convergence

  • Use gene set enrichment analysis with consistent reference databases

  • Implement machine learning approaches to identify patterns across heterogeneous datasets

These methodological approaches facilitate robust comparison and integration of HDAC7 datasets, allowing researchers to identify consistent biological signals despite technical variation between experimental platforms.

What novel therapeutic applications are being explored targeting HDAC7 in disease contexts?

HDAC7-targeted therapeutic strategies are being investigated across several disease contexts:

• Cancer therapeutics:

  • Given HDAC7's role in RAS-transformed cells and cancer stem cell maintenance , selective inhibitors could target cancer stemness

  • Combination therapies coupling HDAC7 inhibitors with conventional chemotherapeutics show promise in overcoming treatment resistance

  • Developing inhibitors that specifically disrupt HDAC7's protein-protein interactions rather than catalytic activity represents a novel approach

• Autoimmune disease interventions:

  • HDAC7's role in tissue-specific autoimmunity suggests targeted modulation could alleviate autoimmune pathology

  • Selective modulation of HDAC7 in specific T-cell populations offers potential for precision medicine approaches

  • Developing agents that regulate HDAC7 phosphorylation status rather than expression presents an alternative intervention strategy

• Experimental approaches for therapeutic development:

  • High-throughput screening assays incorporating HDAC7 phosphorylation status provide platforms for identifying selective modulators

  • Reporter systems monitoring HDAC7 nuclear-cytoplasmic shuttling enable identification of compounds affecting its subcellular localization

  • Patient-derived xenograft models with HDAC7 manipulation allow preclinical assessment of therapeutic potential

Researchers developing HDAC7-targeted therapeutics should implement mechanistic studies to distinguish intended on-target effects from those mediated by impacts on other class IIa HDACs.

What emerging technologies are advancing HDAC7 functional characterization?

Cutting-edge technologies are revolutionizing HDAC7 research approaches:

• Single-cell technologies:

  • Single-cell RNA-seq reveals heterogeneity in HDAC7 expression and activity across cell populations

  • Single-cell ATAC-seq maps chromatin accessibility changes mediated by HDAC7

  • Spatial transcriptomics integrates HDAC7 expression patterns with tissue architecture

• Genome editing advances:

  • CRISPR base editing enables precise modification of HDAC7 phosphorylation sites

  • CRISPR activation/interference systems allow endogenous HDAC7 modulation without overexpression artifacts

  • Prime editing facilitates introduction of specific HDAC7 mutations identified in disease contexts

• Protein interaction and dynamics approaches:

  • Proximity labeling techniques (BioID, APEX) map HDAC7 protein interaction networks in living cells

  • FRET-based biosensors monitor real-time changes in HDAC7 conformation and protein interactions

  • Live-cell imaging of tagged HDAC7 visualizes dynamic shuttling between nuclear and cytoplasmic compartments

• Structural biology innovations:

  • Cryo-EM approaches reveal HDAC7 complex formation with co-repressors

  • Hydrogen-deuterium exchange mass spectrometry maps conformational changes upon phosphorylation

  • Fragment-based drug discovery identifies binding pockets for selective HDAC7 modulation

These technological advances collectively enhance our ability to dissect HDAC7's functions with unprecedented spatial, temporal, and mechanistic resolution.

What unresolved questions represent priority research areas in HDAC7 biology?

Despite significant advances, several critical questions in HDAC7 biology remain unresolved:

• Non-histone substrate identification:

  • Beyond histones, HDAC7 acetylates non-histone proteins like ALKBH5 , but a comprehensive substrate catalog remains undefined

  • Proteome-wide acetylome analysis following HDAC7 manipulation would identify direct deacetylation targets

  • Understanding substrate specificity determinants could explain HDAC7's unique biological functions

• Context-dependent regulatory mechanisms:

  • The molecular basis for HDAC7's opposing effects in different cellular contexts remains poorly understood

  • Identifying tissue-specific cofactors that redirect HDAC7 activity represents a critical knowledge gap

  • Resolving the interplay between phosphorylation at S155 and other post-translational modifications would clarify regulatory mechanisms

• Evolutionary conservation of function:

  • Cross-species comparison of HDAC7 functions, particularly in immune regulation and cancer, remains limited

  • Determining which HDAC7 functions represent fundamental conserved processes versus species-specific adaptations

  • Evolutionary analysis of HDAC7 phosphorylation sites to identify conservation hotspots indicating critical functional domains

• Small molecule modulator development:

  • Creating isoform-selective inhibitors distinguishing HDAC7 from other class IIa HDACs remains challenging

  • Developing agents that modulate specific HDAC7 functions without affecting its entire activity spectrum

  • Identifying natural compounds that selectively influence HDAC7 activity or localization

Addressing these unresolved questions will significantly advance our understanding of HDAC7 biology and its therapeutic potential across multiple disease contexts.